Continue to learn
since 2016
Chengdu Maxvax Biotechnology was founded by Dr. Dexiang Chen in 2016 in China's south-western city of Chengdu. We are a fully integrated biotech dedicated to the development and commercialization of safe and effective immunotherapies to combat current and emerging global health threats utilizing our adjuvant, recombinant protein and mRNA technology platforms. Maxvax has five subsidiaries with over 300 employees and has been recognized as a national high-tech enterprise and a new "small giant" enterprise in Sichuan Province, and has been selected into the GEI China(potential) unicorn enterprise list.
Our mission is to improve global public health through the development of innovative vaccines and immunotherapies to prevent and treat infectious diseases and cancer.
Together with our team and global collaborators, Maxvax has developed a diverse pipeline consisting of both prophylactic and therapeutic vaccines that target some of the most prevalent diseases and global health threats with a focus on infectious disease, allergies, and cancer. Our pipeline products are at various stages of development with two candidates currently in the clinic.
Maxvax is backed by some of the top global venture capitals and investment firms and aimto be a global health player.
Vision
Sense of Worth
Idea